newsroom

Omnix Medical Secures $25 Million Series C to Tackle Antimicrobial Resistance
The Israeli biotech company announced the closing of a $25M Series C funding round aimed at accelerating clinical development of its novel treatment for drug-resistant infections. The funding will enable Omnix Medical to advance toward later-stage trials and expand its impact in the global fight against antimicrobial resistance.

We’re proud to see the company’s continued growth and dedication to improving global health!

At BioGiv, we're proud to support early-stage biotech companies on their journey from lab to life-changing impact. One of our standout success stories from 2024 is Omnix Medical.

Here’s what they accomplished this past year:

Last week, BioGiv had the privilege of attending and presenting at the MIXiii Health-Tech.IL 2025 conference in Jerusalem. It was an incredible opportunity to showcase our mission and connect with so many innovative leaders in the health-tech and life sciences sectors.

The conference was packed with insightful panels, groundbreaking discussions, and fantastic networking opportunities. We were excited to engage with like-minded professionals, share ideas, and explore the future of healthcare technology.